Aconex Ltd beats guidance: Is it a buy?

Aconex Ltd (ASX:ACX) is a niche software provider that the market is betting has significant growth ahead of it.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What: For a company boasting a market capitalisation of $670 million, construction industry software solution provider Aconex Ltd (ASX: ACX) sure has flown under the radar of many investors since its initial public offering (IPO) in December 2014.

It hasn't flown under the radar of all investors however; Aconex's share price has enjoyed a 120% rally since first trading on the ASX!

So What: Aconex might now start to garner more attention from the wider market thanks to the release of its inaugural full year results as a listed company, particularly given those results beat both prospectus forecasts and updated guidance.

Here are the key stats:

  • Revenue up 24% to $82.4 million
  • Australia and New Zealand revenues up 15%
  • International revenues up 33%
  • Earnings before interest, tax, depreciation and amortisation (EBITDA) from core operations of $3 million
  • Net profit after tax (NPAT) a loss of $2.5 million
  • Cash and cash equivalents amounted to $29.1 million reflecting positive cash flow from operations and proceeds from the IPO

Now What: Management noted that Aconex's global market penetration continued to expand including with leading industry players such as Lend Lease Group (ASX: LLC) and Cimic Group Ltd (ASX: CIM) and via winning new customers in the Americas and the Middle East.

Guidance provided for the first half of 2016 is for total revenue of between $51m and $53m, EBITDA from core operations of between $5.5m and $6.5m and NPAT from core operations of between $2.5m and $3.5m.

The half-year guidance suggests the 2016 full year results will show significant growth year-on-year, which is good for shareholders as Aconex's shares appear to have significant growth expectations already priced in.

Motley Fool contributor Tim McArthur has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »